Hybrigenics said that the clinical tolerance observed at high and frequent exposure to Inecalcitol is positive. This makes it possible to consider other potential therapeutic indications such as hormone-dependent prostate cancer and severe psoriasis.
The study showed that all prostate cancer patients tested at 4mg showed good tolerance to this dose of Inecalcitol once a day, and some even twice a day, in addition to the standard Taxotere chemotherapy every three weeks. At this dose, levels of Inecalcitol circulating in the blood after oral administration reached concentrations that have been shown to exert anti-proliferative effects on cancer cells in in-vitro culture, without inducing hypercalcemia.
The clinical tolerance of Inecalcitol offers the opportunity to investigate its therapeutic benefit in the early hormone-dependent stage of prostate cancer, and also possibly in severe psoriasis.
Hybrigenics claimed that Inecalcitol might reach all lesions at the same time by systemic circulation after oral administration without the limitations of hypercalcemia, and exert the beneficial effects of vitamin D on all of them. This is the rationale behind the project to develop Inecalcitol in severe psoriasis in addition to prostate cancer.